119th Congress · introduced in the House · Feb 6, 2025
Shandra Eisenga Human Cell and Tissue Product Safety Act
Official title from Congress.gov
Latest action (Jun 24, 2025): Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Feb 6, 2025)
Shandra Eisenga Human Cell and Tissue Product Safety Act
This bill establishes civil penalties for violations of regulations governing the donation and handling of human cell and tissue products. It also requires the Food and Drug Administration (FDA) to report on the regulation of these products and to provide related information to stakeholders. (Human cell and tissue products are articles containing or consisting of human cells or tissues that are intended for use in a human recipient.)
Specifically, the bill establishes civil penalties for violations of the FDA’s regulations on donor eligibility and current good tissue practice for manufacturing and distributing human cell and tissue products.
Also, the bill requires the FDA to conduct workshops to educate stakeholders and facilitate discussion on the science and regulation of human cell and tissue products. The FDA must establish a public docket to receive written comments on this topic, and report to Congress with recommendations. The bill also requires the FDA to support the development of educational materials for health care professionals regarding organ, tissue, and eye donations and related topics.
Additionally, the bill requires the FDA to publish on its website educational materials about the Tissue Reference Group (a working group within the FDA) and best practices for obtaining a recommendation from them about human cell and tissue products. Also, annually for three years, the FDA must publish on its website information on inquiries submitted to the Tissue Reference Group and FDA registrations and inspections regarding human cell and tissue manufacturers.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H2860-2861)
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H2860-2861)
DEBATE - The House proceeded with forty minutes of debate on H.R. 1082.
Considered under suspension of the rules. (consideration: CR H2860-2862)
Mr. Bilirakis moved to suspend the rules and pass the bill.
Placed on the Union Calendar, Calendar No. 127.
Reported by the Committee on Energy and Commerce. H. Rept. 119-160.
Reported by the Committee on Energy and Commerce. H. Rept. 119-160.
Ordered to be Reported by Voice Vote.
Committee Consideration and Mark-up Session Held
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Administrative law and regulatory procedures · Civil actions and liability · Congressional oversight · Department of Health and Human Services · Health programs administration and funding · Health promotion and preventive care · Organ and tissue donation and transplantation
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
6 citations.
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Medical/Disease Research/Clinical Labs
$360,000
Spent on own lobbying
H.R. 1 One Big Beautiful Bill Act; S.1882, H.R.3589 RESTORE Act; H.R. 1082 Shandra Eisenga Human Cell and Tissue Product Safety Act; HR 1909 Preventing Maternal Deaths Reauthorization Act of 2025; H.R.1418 Purchased and Referred Care…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · lobbying firm or registrant: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 17, 2025 · issue area: Science/Technology
$30,000
Spent on own lobbying
HR 1082, Shandra Eisenga Human Cell and Tissue Product Safety Act HR 5304, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropr…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Family issues/Abortion/Adoption
$490,000
Spent on own lobbying
…ct; S.J.Res. 56, H.J.Res.98 Life Month; H.R.3287 Pregnancy.Gov Act; S.1384, H.R. 2779 Abortion Funding Awareness Act; H.R. 2706 Aid Accountability Act of 2025; H.R. 1082 Shandra Eisenga Human Cell and Tissue Product Safety Act; HR 1909 Preventing Maternal Deaths Reauthorization Act of 2025; H.R.1418 Purchased and Referred Care…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Health Issues
$490,000
Spent on own lobbying
H.R. 1 One Big Beautiful Bill Act; S.1756, H.R.3411 Conscience Protection Act; S.1882, H.R.3589 RESTORE Act; H.R.3287 Pregnancy.Gov Act; H.R. 1082 Shandra Eisenga Human Cell and Tissue Product Safety Act; HR 1909 Preventing Maternal Deaths Reauthorization Act of 2025; H.R.1418 Purchased and Referred Care…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Medical/Disease Research/Clinical Labs
$490,000
Spent on own lobbying
H.R. 1 One Big Beautiful Bill Act; S.1882, H.R.3589 RESTORE Act; H.R. 1082 Shandra Eisenga Human Cell and Tissue Product Safety Act; HR 1909 Preventing Maternal Deaths Reauthorization Act of 2025; H.R.1418 Purchased and Referred Care…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH · lobbying firm or registrant: INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 14, 2025 · issue area: Science/Technology
$30,000
Spent on own lobbying
HR 1082, Shandra Eisenga Human Cell and Tissue Product Safety Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing